Want to see AU:IXC full AI Analyst Report?
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.15
Previous CloseN/A
Volume14.00K
Average Volume (3M)10.33K
Market Cap
AU$8.27M
Enterprise ValueAU$2.75M
Total Cash (Recent Filing)AU$4.02M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Feb 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield248.4%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,153,850
10 Day Avg. Volume5
30 Day Avg. Volume10,328
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces interest obligations and refinancing exposure, giving Invex greater flexibility while it advances its development program. This provides a financial buffer against volatility and preserves more strategic options than a similarly loss-making company carrying material leverage.
Improving Cash-Burn PaceAlthough cash generation has not turned positive, the smaller operating and free-cash-flow outflows in 2025–2026 indicate some improvement in burn control. If sustained, this could extend funding runway and reduce the pace at which additional capital support is required.
Focused IIH Development ProgramA concentrated development strategy around Presendin gives Invex a clear therapeutic objective rather than a broad, unfocused pipeline. Progress in clinical development and regulatory planning could create durable value by establishing a defined route toward a prescription product.
Bears Say
Unstable Revenue And Ongoing LossesThe absence of sustained revenue and continued operating and net losses indicate that the business has not yet demonstrated commercial traction. This weak earnings foundation limits internally funded growth and leaves future results highly dependent on successful development and eventual commercialization.
Persistent Cash BurnPersistent cash burn consumes financial resources while the company continues its development activities, creating an ongoing need for external funding or other balance-sheet support. This can constrain investment flexibility and expose shareholders to financing risk before revenues become established.
Shrinking Equity CushionThe substantial decline in equity shows that accumulated losses have materially reduced the capital cushion supporting the business. Negative returns on equity reinforce that shareholder capital has not generated profits, leaving less financial resilience to absorb setbacks or fund future development.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.09 and its highest was AU$0.15 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$8.27M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Feb 18, 2027 which is in 127 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.008 earnings per share for the quarter.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of 248.4%. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.008 in its last earnings report. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.00%
12-Months-Change
Fundamentals
Return on Equity
-31.98%
Trailing 12-Months
Asset Growth
-25.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Technical Analysis
Acrux
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Argenica Therapeutics Ltd
―
Botanix Pharmaceuticals Limited
―